View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
February 18, 2022

Congestive Heart Failure (Heart Failure) accounts for 12.5% share of global Cardiovascular clinical trial activity in 2021

By Carmen

Congestive Heart Failure (Heart Failure) accounted for a 12.5% share of the global clinical trials within the Cardiovascular therapy area in 2021, registering an increase of 1.6% when compared with the last ten-year average of 10.9% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Congestive Heart Failure

Industry sponsored trials held a 47.1% share of all the clinical trials for Congestive Heart Failure indication in 2021, registering an increase of 8.5% when compared with the ten-year average of 38.6%. Non-industry sponsored trials accounted for a 52.9% share in 2021, marking a decrease of 8.5% over the ten-year average of 61.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Congestive Heart Failure trials

Asia-Pacific was the top region for industry sponsored Congestive Heart Failure trials, accounting for a 53.3% share in 2021, when compared with the five-year average of 55.2% and ten-year average of 46.4%.

Europe was at the second position with a 36.7% share in 2021, over the five-year average of 36.1% and ten-year average of 44.3%, followed by North America with an 18.3% share in 2021, as against five-year and ten-year averages of 32.3% and 31.3% respectively.

Middle East and Africa stood fourth with a 12.5% share in 2021, compared with the five-year average of 8.8% and ten-year average of 8.1%, followed by South and Central America with a 5.0% share in 2021, over five-year and ten-year averages of 8.4% and 7.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Congestive Heart Failure trials, accounting for a 27.5% share in 2021, as against the five-year average of 32.8% and ten-year average of 20.5%.

Russia held a 23.3% share in 2021, over the five-year average of 14.0% and ten-year average of 22.4%, followed by the US with an 18.3% share in 2021, compared with the five-year and ten-year averages of 30.0% and 29.7% respectively.

Japan held a 13.3% share in 2021, as against the five-year average of 9.4% and ten-year average of 9.9%.

The UK held an 8.3% share in 2021, over the five-year and ten-year averages of 14.6% and 13.0% respectively.

Top regions of non-industry sponsored Congestive Heart Failure trials

Asia-Pacific was the top region for non-industry sponsored Congestive Heart Failure trials, accounting for a 53.3% share in 2021 when compared with the five-year average of 36.9% and ten-year average of 37.8%.

Europe was at the second position with a 21.5% share in 2021, over the five-year and ten-year averages of 29.2% and 30.0% respectively, followed by North America with a 17.8% share in 2021, as against the five-year average of 23.9% and ten-year average of 23.6%.

Middle East and Africa stood at the fourth position with a 6.7% share in 2021, compared with the five-year average of 9.4% and ten-year average of 8.3%, followed by South and Central America with a 1.5% share in 2021, over the five-year and ten-year averages of 2.2% and 2.7% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Congestive Heart Failure trials, accounting for a 34.1% share in 2021, as against the five-year average of 18.7% and ten-year average of 12.7%.

The US held a 16.3% share in 2021, over the five-year average of 20.7% and ten-year average of 20.1%, followed by Japan with an 8.9% share, compared with the five-year and ten-year averages of 9.4% and 15.9% respectively.

Spain held a 5.2% share in 2021, as against the five-year average of 4.5% and ten-year average of 3.7%.

The UK held a 4.4% share in 2021, over the five-year average of 3.9% and ten-year average of 4.9%.

Phase I trials lead industry sponsored clinical trials for Congestive Heart Failure in 2021

Phase I trials held a 64.3% share of industry sponsored clinical trials for Congestive Heart Failure in 2021, over the five-year average of 55.9% and ten-year average of 51.7%.

Phase II trials held a 16.3% share in 2021, as against the five-year average of 17.1% and ten-year average of 22.6%. Phase IV trials held an 11.6% share in 2021, compared with the five-year and ten-year averages of 12.2% and 11.4% respectively.

Phase III trials held a 7.8% share in 2021, over the five-year average of 14.9% and ten-year average of 14.3%.

Phase II trials lead non-industry sponsored clinical trials for Congestive Heart Failure in 2021

Phase II trials held a 35.9% share of non-industry sponsored clinical trials for Congestive Heart Failure in 2021, over the five-year average of 39.7% and ten-year average of 44.4%.

Phase IV trials held a 32.4% share in 2021, as against the five-year average of 38.6% and ten-year average of 34.2%. Phase III trials held a 17.2% share, compared with the five-year and ten-year averages of 11.4% and 13.1% respectively.

Phase I trials held a 14.5% share in 2021, over the five-year average of 10.4% and ten-year average of 8.4%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU